Group 1 - Ventas, Inc. (NYSE: VTR) is a real estate investment trust (REIT) focused on the health care sector within the real estate industry [1] - The company is positioned to benefit from the aging population and increasing demand for health care facilities [1] - The investment thesis is bullish, indicating a positive outlook for the company's financial performance and stock price appreciation [1] Group 2 - The article emphasizes the importance of having both long-term and short-term trading strategies for individual investors [1] - The author aims to develop winning trades and improve investment results through focused analysis and feedback [1]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to associated risks and volatility [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system aids in identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - Idexx Laboratories (IDXX) is highlighted as a recommended stock with a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth seen as indicative of strong future prospects [4] - Idexx's historical EPS growth rate is 12.5%, with projected growth for the current year at 14.1%, surpassing the industry average of 13.6% [5] Group 3: Cash Flow Growth - High cash flow growth is essential for growth-oriented companies, allowing them to fund new projects without external financing [6] - Idexx's year-over-year cash flow growth is currently 6%, significantly better than the industry average of -0.8% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 14.6%, compared to the industry average of 6.7% [7] Group 4: Earnings Estimate Revisions - Positive trends in earnings estimate revisions are correlated with stock price movements [8] - Idexx's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 0.1% over the past month [8] Group 5: Overall Assessment - Idexx holds a Zacks Rank of 2 and a Growth Score of B, indicating its potential as an outperformer and a solid choice for growth investors [10]

Manipal Health has acquired a majority stake in Sahyadri Hospitals for about $700 million, adding to a flurry of health care deals in India and challenging the dominance of Apollo Hospitals https://t.co/VTKF8eWZpc ...

>> All right. Welcome back. After a couple years of little activity, the IPO markets picked up with several companies seeing strong debuts.Is it a sign of even better things to come in the months ahead. Let's ask Rick Heitzmann. He's the first Smart Capital founder and partner, and he's with us here at post nine.It's good to see you, man. >> Hey, thanks for having me back. >> What is this, like, an awakening.>> Finally the thawing. There was a gradual thaw last time I was here. I said, hey, there's going to ...

Financial Performance & Guidance - Henry Schein reported FY2022 global net sales of $12.6 billion[8] - In Q1, GAAP diluted EPS was $0.91, and non-GAAP diluted EPS was $1.21[14] - Total sales growth was -3.8% (LCI -3.7%), but excluding PPE & COVID-19 Test Kits, LCI sales growth was strong at 6.3%[18] - EPS was negatively impacted by an estimated $0.24 due to lower contribution from PPE products and COVID-19 Test Kits, $0.04 from acquisition-related expenses, and $0.02 from foreign exchange[18] Henry Schein One & Dental Technology Market - Henry Schein One's 2022 revenue from dental practice management was approximately $550 million[20, 21] - The estimated dental technology market size is $2.3 billion, with an estimated market growth rate of 8-12%[26] - Henry Schein One has 100,000 active dental customers[26] Strategic Priorities & Market Trends - Henry Schein's strategic priorities include building complementary software, specialty, and services, operationalizing One Distribution, leveraging One Schein, and driving digital transformation[9] - Industry trends driving demand for Henry Schein One solutions include payment & claims innovation (72% of dentists are concerned with declining insurance reimbursement rates), AI & clinical decision support, customer dynamics (consumerization of healthcare), and dental practice consolidation[29, 30]

Core Insights - Zacks Premium provides various tools to enhance stock market investment confidence and knowledge [1][2] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, helping investors select stocks with high potential for market outperformance [3][8] Zacks Style Scores Overview - The Zacks Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score [4][5][6][7] - Each stock is rated from A to F based on its characteristics, with A indicating the highest potential for outperformance [4] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [4] Growth Score - Evaluates a company's financial health and future growth potential through earnings, sales, and cash flow analysis [5] Momentum Score - Targets stocks with upward or downward price trends, utilizing recent price changes and earnings estimate shifts [6] VGM Score - Combines Value, Growth, and Momentum Scores to provide a comprehensive assessment of stocks [7] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to identify winning stocks, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] Stock Recommendation: McKesson Corporation - McKesson Corporation, a healthcare services and IT company, holds a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong growth potential [13] - The company is projected to have a year-over-year earnings growth of 12.7% for the current fiscal year, supported by positive earnings estimate revisions [14]

My next guest has uh compared to the rest of the world, the US labor market is outperforming even with all of these uncertainties that rage. Consumer demand he thinks is also resilient. Evans S is CEO of global workforce data and analytic company Aura Intelligence.Evan like 87 questions. I'll try to jam into just a few here. Um starting with and and Michael Caneritz was on at the top of the show saying he thinks any slowdown we're going to see on the jobs front is not necessarily a recessionary one.Um it so ...

Let me ask you, have you ever met just a nurse? Have you ever heard someone say, "I'm just the nurse. " Well, I've been just the nurse for 38 years. I'm here to tell you there is nothing just about it. I'm the oldest of five children in a very traditional family, which is to say, I was the first to think of going off to college. So, one day, my dad and I were having a serious conversation about what career I envisioned for myself and what future I thought I might have. You see, I had it narrowed down to law ...

Today, the conservative majority on the United States Supreme Court ruled that states can effectively defund Planned Parenthood, the country's largest provider of reproductive health care. In a 63 ruling, the court changed federal law allowing states to unilaterally cut off all Medicaid funding from Planned Parenthood simply on the basis that it provides abortion care. Now, to be clear, abortion makes up only 3%. Abortion care only makes up 3% of Planned Parenthood services.It is a crucial 3% but it's 3%. T ...

19 June 2025 Equity Research Report China Healthcare Equities Demand for innovative drug clinical trials shifting to China amid supportive policies China's clinical efficiency leap: Catching up with the world with strengthened competitiveness. The National Medical Product Administration (NMPA) published a circular in June, proposing to reduce the review and approval time of clinical trial applications for all innovative drugs to 30 days from the previous 60 days, following the pilot programme in July 2024. ...